Nora Zulehner Selected Research

Breast Neoplasms (Breast Cancer)

11/2012	PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
4/2011	Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
3/2011	Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
1/2011	Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
1/2011	Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
1/2011	Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nora Zulehner Research Topics

Disease

7	Neoplasms (Cancer) 11/2012 - 01/2011
6	Breast Neoplasms (Breast Cancer) 11/2012 - 01/2011
1	Hypersensitivity (Allergy) 01/2014
1	Seasonal Allergic Rhinitis (Hay Fever) 01/2014
1	Genomic Instability 11/2012
1	Ovarian Neoplasms (Ovarian Cancer) 11/2012
1	Adenocarcinoma of Lung 01/2011
1	Lung Neoplasms (Lung Cancer) 01/2011

Drug/Important Bio-Agent (IBA)

5	Cyclin-Dependent Kinases (cdk Proteins)IBA 04/2011 - 01/2011
5	RoscovitineIBA 04/2011 - 01/2011
3	Proteins (Proteins, Gene)FDA Link 01/2014 - 02/2011
3	DNA (Deoxyribonucleic Acid)IBA 11/2012 - 01/2011
3	Estrogens (Estrogen)FDA Link 04/2011 - 01/2011
3	Tamoxifen FDA LinkGeneric 03/2011 - 01/2011
2	Hormones (Hormone)IBA 03/2011 - 01/2011
2	SteroidsIBA 03/2011 - 01/2011
1	AllergensIBA 01/2014
1	A-factor (Streptomyces)IBA 01/2014
1	C 1305IBA 11/2012
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 11/2012
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 11/2012
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2012
1	Estrogen ReceptorsIBA 03/2011
1	Selective Estrogen Receptor Modulators (SERM)IBA 03/2011
1	Cyclin-Dependent Kinase Inhibitor p16IBA 02/2011
1	CyclinsIBA 02/2011
1	Caspase 3 (Caspase-3)IBA 01/2011
1	Adenosine Triphosphate (ATP)IBA 01/2011
1	Cisplatin (Platino)FDA LinkGeneric 01/2011
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2011

Therapy/Procedure

1	Therapeutics 01/2011